Company intelligence / Profile preview
Gen Ilac Ve Saglik Urunleri
Çankaya, Ankara, Turkey
- Ownership
- Public · GENIL
- Employees
- ~619
- Development stage
- Other
01
Overview
GEN specializes in solutions for rare diseases and unmet medical needs, with commercialized products and ongoing R&D collaborations including SUL-238 (with Sulfateq BV) for neurodegenerative diseases like Alzheimer's[1][3][5].
- Therapeutic areas
- EndocrinologyNephrologyRare DiseasesHematologyOtherOncologyNeurology
- Modalities
- Small moleculeBiologicMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sulfateq BV (R&D, SUL-238 for neurodegenerative diseases)[1]Santhera Pharmaceuticals (distribution for Vamorolone in Turkey)[4]
Beyond the preview
Go deeper on Gen Ilac Ve Saglik Urunleri.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gen Ilac Ve Saglik Urunleri.